可引起儿童急性肝衰竭的遗传代谢病

梁欢; 张惠文

doi:10.3969/j.issn.1001-5256.2022.02.005

可引起儿童急性肝衰竭的遗传代谢病

DOI: 10.3969/j.issn.1001-5256.2022.02.005

梁欢,
张惠文^,

上海交通大学医学院附属新华医院, 上海市儿科医学研究所儿童内分泌与遗传科, 上海 200092

基金项目:

上海市科委自然科学基金 (20ZR1446300)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：梁欢负责文献收集及撰写论文；张惠文负责拟定写作思路并最后定稿。

详细信息

通信作者:
张惠文, zhanghuiwen@xinhuamed.com.cn

计量
- 文章访问数: 823
- HTML全文浏览量: 211
- PDF下载量: 70
- 被引次数: 0
出版历程
- 收稿日期: 2021-10-15
- 录用日期: 2021-11-16
- 出版日期: 2022-02-20

Inherited metabolic diseases causing acute liver failure in children

Huan LIANG,
Huiwen ZHANG^,

Department of Pediatric Endocrinology and Genetic Metabolism, Shanghai Institute for Pediatric Research, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China

Research funding:

Natural Science Foundation of Science and Technology Commission of Shanghai Municipality (20ZR1446300)

More Information

Corresponding author: ZHANG Huiwen, zhanghuiwen@xinhuamed.com.cn

摘要

摘要: 引起儿童急性肝衰竭(ALF)的病因较为复杂, 其中遗传代谢病占比较高, 特别是在婴幼儿时期。遗传代谢病是一类代谢相关基因突变导致的细胞生理功能破坏的先天性疾病, 种类繁多, 临床表现多样, ALF是其引起的严重并发症之一, 由于部分缺乏特异性表现容易被忽视。应尽早识别这类病因引起的ALF, 以期逆转ALF的进程, 提高患者预后。本文对可引起儿童ALF的常见遗传代谢病予以归纳介绍, 以期提高医生对此类病因的认识。
- 肝功能衰竭, 急性 /
- 遗传性疾病, 先天性 /
- 诊断
Abstract: Acute liver failure (ALF) in children has complex etiologies, among which inherited metabolic diseases account for a high proportion, especially in infants and young children. Inherited metabolic diseases are a group of congenital diseases with destruction of cell physiological function caused by metabolism-related gene mutations, with various types and diverse clinical manifestations. ALF is one of the serious complications caused by such diseases and is easily neglected due to a lack of specific manifestations. ALF caused by such etiologies should be identified as early as possible to reverse the progression of ALF and improve the prognosis of patients. This article summarizes the common inherited metabolic diseases that can cause ALF in children, in order to improve the awareness of such etiology among physicians.
- Liver Failure, Acute /
- Genetic Diseases, Inborn /
- Diagnosis

HTML全文

参考文献(42)

[1]	JIANG T, OUYANG WX, TAN YF, et al. Analysis of etiology and prognosis of 120 children with pediatric acute liver failure[J]. Chin J Appl Clin Pediatr, 2020, 35(6): 422-425. DOI: 10.3760/cma.j.cn101070-20191108-01113. 姜涛, 欧阳文献, 谭艳芳, 等. 儿童急性肝衰竭120例病因和预后分析[J]. 中华实用儿科临床杂志, 2020, 35(6): 422-425. DOI: 10.3760/cma.j.cn101070-20191108-01113.
[2]	ALAM S, LAL BB. Metabolic liver diseases presenting as acute liver failure in children[J]. Indian Pediatr, 2016, 53(8): 695-701. DOI: 10.1007/s13312-016-0913-1.
[3]	LAEMMLE A, GALLAGHER RC, KEOGH A, et al. Frequency and pathophysiology of acute liver failure in ornithine transcarbamylase deficiency (OTCD)[J]. PLoS One, 2016, 11(4): e0153358. DOI: 10.1371/journal.pone.0153358.
[4]	GALLAGHER RC, LAM C, WONG D, et al. Significant hepatic involvement in patients with ornithine transcarbamylase deficiency[J]. J Pediatr, 2014, 164(4): 720-725. DOI: 10.1016/j.jpeds.2013.12.024.
[5]	CICHOŻ-LACH H, MICHALAK A. Current pathogenetic aspects of hepatic encephalopathy and noncirrhotic hyperammonemic encephalopathy[J]. World J Gastroenterol, 2013, 19(1): 26-34. DOI: 10.3748/wjg.v19.i1.26.
[6]	HAYASAKA K. Metabolic basis and treatment of citrin deficiency[J]. J Inherit Metab Dis, 2021, 44(1): 110-117. DOI: 10.1002/jimd.12294.
[7]	CLARKSTON K, LEE J, DONOGHUE S, et al. Acute liver dysfunction with delayed peak of serum aminotransferase levels as a presentation of ornithine transcarbamylase deficiency in females[J]. Am J Med Genet A, 2021, 185(3): 909-915. DOI: 10.1002/ajmg.a.62031.
[8]	CHONGSRISAWAT V, DAMRONGPHOL P, ITTIWUT C, et al. The phenotypic and mutational spectrum of Thai female patients with ornithine transcarbamylase deficiency[J]. Gene, 2018, 679: 377-381. DOI: 10.1016/j.gene.2018.09.026.
[9]	HÄBERLE J, BURLINA A, CHAKRAPANI A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: First revision[J]. J Inherit Metab Dis, 2019, 42(6): 1192-1230. DOI: 10.1002/jimd.12100.
[10]	OZANNE B, NELSON J, COUSINEAU J, et al. Threshold for toxicity from hyperammonemia in critically ill children[J]. J Hepatol, 2012, 56(1): 123-128. DOI: 10.1016/j.jhep.2011.03.021.
[11]	de LAS HERAS J, ALDÁMIZ-ECHEVARRÍA L, MARTÍNEZ-CHANTAR ML, et al. An update on the use of benzoate, phenylacetate and phenylbutyrate ammonia scavengers for interrogating and modifying liver nitrogen metabolism and its implications in urea cycle disorders and liver disease[J]. Expert Opin Drug Metab Toxicol, 2017, 13(4): 439-448. DOI: 10.1080/17425255.2017.1262843.
[12]	TEUFEL U, WEITZ J, FLECHTENMACHER C, et al. High urgency liver transplantation in ornithine transcarbamylase deficiency presenting with acute liver failure[J]. Pediatr Transplant, 2011, 15(6): e110-e115. DOI: 10.1111/j.1399-3046.2009.01171.x.
[13]	KIDO J, MATSUMOTO S, HÄBERLE J, et al. Role of liver transplantation in urea cycle disorders: Report from a nationwide study in Japan[J]. J Inherit Metab Dis, 2021, 44(6): 1311-1322. DOI: 10.1002/jimd.12415.
[14]	WAKIYA T, SANADA Y, MIZUTA K, et al. Living donor liver transplantation for ornithine transcarbamylase deficiency[J]. Pediatr Transplant, 2011, 15(4): 390-395. DOI: 10.1111/j.1399-3046.2011.01494.x.
[15]	TANGUAY RM, ANGILERI F, VOGEL A. Molecular pathogenesis of liver injury in hereditary tyrosinemia 1[J]. Adv Exp Med Biol, 2017, 959: 49-64. DOI: 10.1007/978-3-319-55780-9_4.
[16]	SCOTT CR. The genetic tyrosinemias[J]. Am J Med Genet C Semin Med Genet, 2006, 142C(2): 121-126. DOI: 10.1002/ajmg.c.30092.
[17]	DAOU KN, BARHOUMI A, BASSYOUNI A, et al. Diagnostic and therapeutic challenges of hereditary tyrosinemia type 1 in Lebanon: A 12-year retrospective review[J]. Front Pediatr, 2021, 9: 698577. DOI: 10.3389/fped.2021.698577.
[18]	van SPRONSEN FJ, THOMASSE Y, SMIT GP, et al. Hereditary tyrosinemia type Ⅰ: A new clinical classification with difference in prognosis on dietary treatment[J]. Hepatology, 1994, 20(5): 1187-1191. DOI: 10.1002/hep.1840200513
[19]	SPIEKERKOETTER U, COUCE ML, DAS AM, et al. Long-term safety and outcomes in hereditary tyrosinaemia type 1 with nitisinone treatment: A 15-year non-interventional, multicentre study[J]. Lancet Diabetes Endocrinol, 2021, 9(7): 427-435. DOI: 10.1016/S2213-8587(21)00092-9.
[20]	HOLME E, LINDSTEDT S. Nontransplant treatment of tyrosinemia[J]. Clin Liver Dis, 2000, 4(4): 805-814. DOI: 10.1016/s1089-3261(05)70142-2.
[21]	GIL-MARTÍNEZ J, MACIAS I, UNIONE L, et al. Therapeutic targeting of fumaryl acetoacetate hydrolase in hereditary tyrosinemia type Ⅰ[J]. Int J Mol Sci, 2021, 22(4): 1789. DOI: 10.3390/ijms22041789.
[22]	GU P, YANG Q, CHEN B, et al. Genetically blocking HPD via CRISPR-Cas9 protects against lethal liver injury in a pig model of tyrosinemia type Ⅰ[J]. Mol Ther Methods Clin Dev, 2021, 21: 530-547. DOI: 10.1016/j.omtm.2021.04.002.
[23]	BIGOT A, TCHAN MC, THOREAU B, et al. Liver involvement in urea cycle disorders: A review of the literature[J]. J Inherit Metab Dis, 2017, 40(6): 757-769. DOI: 10.1007/s10545-017-0088-5.
[24]	ZHANG MH, GONG JY, WANG JS. Citrin deficiency presenting as acute liver failure in an eight-month-old infant[J]. World J Gastroenterol, 2015, 21(23): 7331-7334. DOI: 10.3748/wjg.v21.i23.7331.
[25]	FERNÁNDEZ TOMÉ L, STARK AROEIRA LG, MUÑOZ BARTOLO G, et al. Citrin deficiency: Early severe cases in a European country[J]. Clin Res Hepatol Gastroenterol, 2021, 45(4): 101595. DOI: 10.1016/j.clinre.2020.101595.
[26]	GUNAYDIN M, BOZKURTER CIL AT. Progressive familial intrahepatic cholestasis: Diagnosis, management, and treatment[J]. Hepat Med, 2018, 10: 95-104. DOI: 10.2147/HMER.S137209.
[27]	GÜL-KLEIN S, ÖLLINGER R, SCHMELZLE M, et al. Long-term outcome after liver transplantation for progressive familial intrahepatic cholestasis[J]. Medicina (Kaunas), 2021, 57(8): 854. DOI: 10.3390/medicina57080854.
[28]	LIU Y, SUN LY, ZHU ZJ, et al. Liver transplantation for progressive familial intrahepatic cholestasis[J]. Ann Transplant, 2018, 23: 666-673. DOI: 10.12659/AOT.909941.
[29]	GONZALES E, GROSSE B, SCHULLER B, et al. Targeted pharmacotherapy in progressive familial intrahepatic cholestasis type 2: Evidence for improvement of cholestasis with 4-phenylbutyrate[J]. Hepatology, 2015, 62(2): 558-566. DOI: 10.1002/hep.27767.
[30]	ENGELMANN G, WENNING D, HEREBIAN D, et al. Two case reports of successful treatment of cholestasis with steroids in patients with PFIC-2[J]. Pediatrics, 2015, 135(5): e1326-e1332. DOI: 10.1542/peds.2014-2376.
[31]	ANDERSON S. GALT deficiency galactosemia[J]. MCN Am J Matern Child Nurs, 2018, 43(1): 44-51. DOI: 10.1097/NMC.0000000000000388.
[32]	GRAMA A, BLAGA L, NICOLESCU A, et al. Novel mutation in GALT gene in galactosemia patient with group B streptococcus meningitis and acute liver failure[J]. Medicina (Kaunas), 2019, 55(4): 91. DOI: 10.3390/medicina55040091.
[33]	LI H, BYERS HM, DIAZ-KUAN A, et al. Acute liver failure in neonates with undiagnosed hereditary fructose intolerance due to exposure from widely available infant formulas[J]. Mol Genet Metab, 2018, 123(4): 428-432. DOI: 10.1016/j.ymgme.2018.02.016.
[34]	DI DATO F, SPADARELLA S, PUOTI MG, et al. Daily fructose traces intake and liver injury in children with hereditary fructose intolerance[J]. Nutrients, 2019, 11(10): 2397. DOI: 10.3390/nu11102397.
[35]	WASSERSTEIN MP, DESNICK RJ, SCHUCHMAN EH, et al. The natural history of type B Niemann-Pick disease: Results from a 10-year longitudinal study[J]. Pediatrics, 2004, 114(6): e672-e677. DOI: 10.1542/peds.2004-0887.
[36]	DIAZ GA, JONES SA, SCARPA M, et al. One-year results of a clinical trial of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency[J]. Genet Med, 2021, 23(8): 1543-1550. DOI: 10.1038/s41436-021-01156-3.
[37]	PINEDA M, WALTERFANG M, PATTERSON MC. Miglustat in Niemann-Pick disease type C patients: A review[J]. Orphanet J Rare Dis, 2018, 13(1): 140. DOI: 10.1186/s13023-018-0844-0.
[38]	PATTERSON MC, GARVER WS, GIUGLIANI R, et al. Long-term survival outcomes of patients with Niemann-Pick disease type C receiving miglustat treatment: A large retrospective observational study[J]. J Inherit Metab Dis, 2020, 43(5): 1060-1069. DOI: 10.1002/jimd.12245.
[39]	ODAIB AA, SHNEIDER BL, BENNETT MJ, et al. A defect in the transport of long-chain fatty acids associated with acute liver failure[J]. N Engl J Med, 1998, 339(24): 1752-1757. DOI: 10.1056/NEJM199812103392405.
[40]	WAJNER M, AMARAL AU. Mitochondrial dysfunction in fatty acid oxidation disorders: Insights from human and animal studies[J]. Biosci Rep, 2015, 36(1): e00281. DOI: 10.1042/BSR20150240.
[41]	MERRITT JL 2nd, MACLEOD E, JURECKA A, et al. Clinical manifestations and management of fatty acid oxidation disorders[J]. Rev Endocr Metab Disord, 2020, 21(4): 479-493. DOI: 10.1007/s11154-020-09568-3.
[42]	YAMADA K, TAKETANI T. Management and diagnosis of mitochondrial fatty acid oxidation disorders: Focus on very-long-chain acyl-CoA dehydrogenase deficiency[J]. J Hum Genet, 2019, 64(2): 73-85. DOI: 10.1038/s10038-018-0527-7.